SCHEMBL6550216

SCHEMBL6550216

O=C(O)c1ccc(Cl)c(S(=O)(=O)NCc2cccc(Cl)c2Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.62
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ HTT P42858 1/20 0.50
▸ MCL1 Q07820 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ SLC25A1 P53007 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ LMNA P02545 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ SLC12A2 P55011 1/20 0.47
▸ SLC12A5 Q9H2X9 1/20 0.47
▸ SLC16A3 O15427 1/20 0.47
▸ GPR55 Q9Y2T6 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11598628 0.90 POLB (0.65) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL11712963 0.84 POLB (0.61) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL18723228 0.82 POLB (0.75) POLBL3MBTL1TDP1NPSR1HTT
SCHEMBL6550219 0.81 POLB (0.60) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL6550108 0.81 POLB (0.60) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL11596782 0.80 LMNA (0.57) POLBL3MBTL1TDP1HTTMCL1
SCHEMBL11596689 0.79 LMNA (0.56) POLBL3MBTL1TDP1HTTMCL1
SCHEMBL11596906 0.78 LMNA (0.55) POLBL3MBTL1TDP1MCL1KMT2A
SCHEMBL11344085 0.77 MAPT (0.53) POLBL3MBTL1TDP1NPSR1HTT
SCHEMBL11531085 0.77 LMNA (0.54) POLBL3MBTL1TDP1MCL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1341754-B1 SUBSTITUTED ANTHRANILIC ACIDS AVENTIS PHARMA GMBH (DE) 2004-12-08 — — EP disclosed
EP-1341754-A1 SUBSTITUTED ANTHRANILIC ACIDS Aventis Pharma Deutschland GmbH (DE) 2003-09-10 — — EP disclosed
US-6593352-B2 2-phenylalkylaminobenzoic acid containing substituted benzylsufamoyl group; useful for treating cardiovascular disorders, and for preserving or storing a transplant for surgery AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-07-15 — — US disclosed
US-20020123632-A1 Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-09-05 — — US disclosed
WO-2002046148-A1 SUBSTITUTED ANTHRANILIC ACIDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123632-A1 Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker SLC10A1, SLC9A1, SLC9A2 POLB 2938/4885L3MBTL1 4881/4885TDP1 4130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback